直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • News
  • Finnegan Facts
  • History
    • Finnegan VISION
    • Finnegan FORWARD
  • Pro Bono
  • Management
    • Pricing & Alternative Fee Arrangements
    • AFA Models We Offer
    • Contingency Fees
    • AI + KM

Media Mention

Eli Lilly Subsidiary Gets $3.9M in Fees Under Octane Ruling

August 17, 2016

Law360

On August 17, 2016, a Pennsylvania federal judge approved a special master's recommendation of $3.9 million in fees to Finnegan client Avid Radiopharmaceuticals. The fees were awarded to Avid for its expenses defending a bad-faith patent suit by Alzheimer's Institute of America (AIA).

The fee request came as a result of a November 2010 patent infringement suit that AIA filed against Avid and the University of Pennsylvania (U Penn), alleging that Avid and U Penn infringed two of its patents. In March 2015, a judge ruled the case was "exceptional" under the 2014 Octane Fitness decision, on the basis that AIA knew that it wasn't the legal owner of the patent when they filed the suit, thus entitling Avid and Penn to attorneys' fees to defend a bad-faith action.

Related Practices

Global IP Enforcement, Litigation, and Trials

Related Industries

Life Sciences

Pharmaceutical

Related News

Award/Ranking

Finnegan Earns Top Rankings in 2026 IAM Patent 1000 Guide; Nearly 60 Attorneys Ranked

May 28, 2026

Commentary

Quince Aims to Have ‘Dupe’ Evidence Shape Ugg Shoe Patent Trial

May 26, 2026

Commentary

New Appellate Opinion in Amazon Biometric Data Case May Signal ‘Narrowing’ Scope of BIPA Litigation, Experts Say

May 20, 2026

Award/Ranking

Finnegan Partner Antje Brambrink Shortlisted for Women in Business Law EMEA Award

May 13, 2026

Press Release

Finnegan Secures Decisive ITC Victory for Innoscience in Final Determination

May 11, 2026

Commentary

ITC Bars Import of Innoscience Chips Made Before Redesign

May 8, 2026

Commentary

How Litigation Funding Disclosure Could Affect ITC Cases

May 7 , 2026

Award/Ranking

Associates Rank Finnegan “Best of the Best” in BTI Associate Satisfaction Survey

May 7, 2026

Commentary

Justices to Side with Generic Drugmakers in Patent Spat, Attorneys Predict

May 5, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP